Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
Due to the logistical considerations, UCB has decided to consolidate the Phase II and Phase III open-label extension trials. Subjects completing this study will be offered the option of continuing to receive epratuzumab through participation in Phase III open-label extension study SL0012 (NCT01408576).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have participated in SL0003 or SL0004 and benefitted from participation in those studies
You may not be if
Development of toxicity to epratuzumab
Significant protocol deviations during the SL0003 or SL0004 studies
